Short Interest in Bone Biologics Co. (NASDAQ:BBLG) Grows By 21.0%

Bone Biologics Co. (NASDAQ:BBLG) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 70,400 shares, an increase of 21.0% from the November 15th total of 58,200 shares. Currently, 13.2% of the shares of the stock are sold short. Based on an average daily volume of 3,010,000 shares, the short-interest ratio is currently 0.0 days.

Bone Biologics Stock Down 1.8 %

Shares of NASDAQ BBLG traded down $0.02 during midday trading on Friday, reaching $1.12. The company’s stock had a trading volume of 32,293 shares, compared to its average volume of 1,414,019. Bone Biologics has a one year low of $0.80 and a one year high of $10.56. The company has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.50.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.